Jerusalem Pharmaceuticals Co. Ltd. (PEX:JPH)
4.650
0.00 (0.00%)
At close: Mar 4, 2026
Jerusalem Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 11.98 | 11.74 | 6.59 | 7.73 | 5.44 | Upgrade
|
| Short-Term Investments | 9.88 | 0.09 | 0.05 | 0.03 | 0.03 | Upgrade
|
| Trading Asset Securities | - | - | - | 0.03 | 0.03 | Upgrade
|
| Cash & Short-Term Investments | 21.85 | 11.84 | 6.64 | 7.79 | 5.49 | Upgrade
|
| Cash Growth | 84.62% | 78.27% | -14.72% | 41.69% | 171.63% | Upgrade
|
| Accounts Receivable | 35.9 | 28.25 | 29.95 | 31.63 | 30.81 | Upgrade
|
| Other Receivables | - | - | 0 | - | - | Upgrade
|
| Receivables | 35.9 | 28.25 | 29.95 | 31.63 | 30.81 | Upgrade
|
| Inventory | 13.05 | 8.34 | 10.41 | 10.88 | 14.76 | Upgrade
|
| Prepaid Expenses | - | 0.31 | 0.51 | 0.4 | 0.73 | Upgrade
|
| Other Current Assets | 2.7 | 2.8 | 3.1 | 2.22 | 3.33 | Upgrade
|
| Total Current Assets | 73.5 | 51.54 | 50.61 | 52.91 | 55.12 | Upgrade
|
| Property, Plant & Equipment | 28.83 | 25.9 | 27.13 | 25.48 | 27.47 | Upgrade
|
| Long-Term Investments | 4.36 | 7.24 | 6.42 | 3.22 | 0.7 | Upgrade
|
| Other Intangible Assets | 2.62 | 1.8 | 1.55 | 1.52 | 3.04 | Upgrade
|
| Long-Term Deferred Tax Assets | 0.56 | 0.4 | 0.28 | 0.27 | 0.2 | Upgrade
|
| Other Long-Term Assets | 2.6 | 2.27 | 0.32 | 0.32 | 0.37 | Upgrade
|
| Total Assets | 112.46 | 89.15 | 86.32 | 83.72 | 86.89 | Upgrade
|
| Accounts Payable | 5.28 | 3.29 | 3.48 | 6.56 | 5.11 | Upgrade
|
| Accrued Expenses | - | 3.58 | 2.33 | 1.32 | 1.99 | Upgrade
|
| Short-Term Debt | 0.72 | 0.46 | 0.52 | 0.65 | 0.78 | Upgrade
|
| Current Portion of Long-Term Debt | - | 0.61 | 1.13 | 0.69 | 0.57 | Upgrade
|
| Current Portion of Leases | 0.44 | 0.3 | 0.48 | 0.36 | 0.55 | Upgrade
|
| Current Income Taxes Payable | 3.51 | 1.29 | 2.42 | 2.67 | 1.66 | Upgrade
|
| Other Current Liabilities | 7.26 | 2.46 | 1.95 | 1.46 | 2.3 | Upgrade
|
| Total Current Liabilities | 17.2 | 12 | 12.32 | 13.7 | 12.97 | Upgrade
|
| Long-Term Leases | 0.16 | 0.14 | 0.33 | 0.49 | 0.72 | Upgrade
|
| Long-Term Unearned Revenue | 0.53 | 0.29 | - | - | - | Upgrade
|
| Pension & Post-Retirement Benefits | 6.36 | 5.12 | 4.79 | 4.3 | 4.64 | Upgrade
|
| Total Liabilities | 24.26 | 17.55 | 17.44 | 18.49 | 18.32 | Upgrade
|
| Common Stock | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Additional Paid-In Capital | 3.72 | 3.72 | 3.72 | 3.72 | 3.72 | Upgrade
|
| Retained Earnings | 51.63 | 42.83 | 39.6 | 34.9 | 29.89 | Upgrade
|
| Comprehensive Income & Other | 13.77 | 6.04 | 6.52 | 7.65 | 14.87 | Upgrade
|
| Total Common Equity | 87.12 | 70.6 | 67.84 | 64.27 | 66.47 | Upgrade
|
| Minority Interest | 1.08 | 1.01 | 1.04 | 0.96 | 2.1 | Upgrade
|
| Shareholders' Equity | 88.2 | 71.61 | 68.88 | 65.23 | 68.57 | Upgrade
|
| Total Liabilities & Equity | 112.46 | 89.15 | 86.32 | 83.72 | 86.89 | Upgrade
|
| Total Debt | 1.32 | 1.51 | 2.47 | 2.18 | 2.63 | Upgrade
|
| Net Cash (Debt) | 20.53 | 10.32 | 4.17 | 5.6 | 2.86 | Upgrade
|
| Net Cash Growth | 98.89% | 147.75% | -25.64% | 95.69% | - | Upgrade
|
| Net Cash Per Share | 1.14 | 0.57 | 0.23 | 0.31 | 0.16 | Upgrade
|
| Filing Date Shares Outstanding | 18.04 | 18 | 18 | 18 | 18 | Upgrade
|
| Total Common Shares Outstanding | 18.04 | 18 | 18 | 18 | 18 | Upgrade
|
| Working Capital | 56.29 | 39.53 | 38.28 | 39.2 | 42.16 | Upgrade
|
| Book Value Per Share | 4.83 | 3.92 | 3.77 | 3.57 | 3.69 | Upgrade
|
| Tangible Book Value | 84.5 | 68.8 | 66.29 | 62.75 | 63.43 | Upgrade
|
| Tangible Book Value Per Share | 4.69 | 3.82 | 3.68 | 3.49 | 3.52 | Upgrade
|
| Land | - | 9.49 | 10.63 | 9.24 | 8.31 | Upgrade
|
| Buildings | - | 15.42 | 15.64 | 15.73 | 16.34 | Upgrade
|
| Machinery | - | 30.8 | 29.47 | 28.78 | 31.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.